BioXcel Therapeutics, Inc. Shareholders' Equity
BioXcel Therapeutics, Inc. (BTAI) had Shareholders' Equity of -$115.46 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-13
- 2026-06-30: Stockholders' Equity Attributable to Parent -$115.46M.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$105.54M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$95.46M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$88.92M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | -$115.46M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$105.54M 10-Q · filed 2026-08-13 | |
| 2025-12-31 | -$95.46M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | -$88.92M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | -$107.67M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | -$90.17M 10-Q · filed 2026-08-13 | |
| 2024-12-31 | -$93.10M 10-Q · filed 2026-08-13 | |
| 2024-09-30 | -$85.63M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$74.30M 10-Q · filed 2025-11-12 | |
| 2024-03-31 | -$72.36M 10-Q · filed 2025-11-12 | |
| 2023-12-31 | -$56.51M 10-K · filed 2026-03-27 | |
| 2023-09-30 | -$40.61M 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $5.86M 10-Q · filed 2024-11-14 | |
| 2023-03-31 | $53.01M 10-Q · filed 2024-11-14 | |
| 2022-12-31 | $76.78M 10-K · filed 2025-03-28 | |
| 2022-09-30 | $126.99M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $164.26M 10-Q · filed 2023-11-14 | $164.26M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $194.02M 10-Q · filed 2023-11-14 | |
| 2021-12-31 | $221.67M 10-K · filed 2024-03-22 | |
| 2021-09-30 | $245.56M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $267.41M 10-Q · filed 2022-11-14 | |
| 2021-03-31 | $186.74M 10-Q · filed 2022-11-14 | |
| 2020-12-31 | $206.70M 10-K · filed 2023-03-16 | |
| 2020-09-30 | $220.94M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $53.39M 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $72.59M 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $26.89M 10-K · filed 2022-03-11 | |
| 2019-09-30 | $34.42M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $25.16M 10-Q · filed 2020-11-12 | |
| 2019-03-31 | $32.37M 10-Q · filed 2020-11-12 | |
| 2018-12-31 | $38.89M 10-K · filed 2021-03-12 | |
| 2018-09-30 | $45.82M 10-Q · filed 2019-11-14 | |
| 2018-06-30 | $49.82M 10-Q · filed 2019-11-14 | |
| 2018-03-31 | $52.11M 10-Q · filed 2019-11-14 | $52.11M 10-Q · filed 2018-05-14 |
| 2017-12-31 | -$982.00K 10-K · filed 2020-03-09 | |
| 2017-03-29 | -$314.00K 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |